The Gross Margin of Scholar Rock Holding Corporation (SRRK) is
7775.20%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2024-12-31 |
7775.20%
|
| Ticker |
Name |
Value |
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
PGEN
|
Precigen, Inc.
|
50.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
XENE
|
Xenon Pharmaceuticals Inc.
|
7775.20%
|
|
ADAG
|
Adagene Inc.
|
7775.20%
|
|
KDMN
|
Kadmon Holdings Inc
|
75.87%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
RNA
|
Atrium Therapeutics Inc
|
7775.20%
|
|
HRTX
|
Heron Therapeutics Inc
|
73.31%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
ENTA
|
Enanta Pharmaceuticals Inc
|
100.00%
|
|
HGEN
|
Humanigen Inc
|
7775.20%
|
|
MDXG
|
MiMedx Group, Inc.
|
82.56%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
46.82%
|
|
STRO
|
Sutro Biopharma Inc
|
7775.20%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
MGNX
|
MacroGenics Inc
|
75.91%
|
|
MGTX
|
MeiraGTx Holdings PLC
|
94.05%
|
|
MNKD
|
MannKind Corporation
|
77.77%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
75.62%
|
|
XNCR
|
Xencor, Inc.
|
7775.20%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
97.82%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
97.89%
|
|
CVM
|
CEL-SCI Corp
|
7775.20%
|
|
CDMO
|
Avid Bioservices Inc
|
5.23%
|
|
CRIS
|
Curis Inc
|
99.52%
|
|
EDIT
|
Editas Medicine, Inc.
|
7775.20%
|
|
VCEL
|
Vericel Corporation
|
74.42%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
CLDX
|
Celldex Therapeutics, Inc.
|
100.00%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
LXRX
|
Lexicon Pharmaceuticals, Inc.
|
99.45%
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
94.14%
|
|
MORF
|
Morphic Holding Inc
|
7775.20%
|
|
ZNTL
|
Zentalis Pharmaceuticals, Inc.
|
7775.20%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|